BLAINJECTIONINJECTABLE1 Generic Approved
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
COSENTYX (secukinumab) by Novartis is interleukin-17a antagonists [moa]. Approved for interleukin-17a antagonist [epc]. First approved in 2023.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COSENTYX (secukinumab) is a fully human monoclonal antibody that selectively targets and inhibits interleukin-17A, a key cytokine in inflammatory and autoimmune disease pathways. It is approved for multiple indications including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and other IL-17A-driven conditions. The drug works by blocking IL-17A signaling, thereby reducing inflammatory responses in affected tissues.
Growth
COSENTYX is in active growth phase with moderate competitive pressure (30%), signaling expanding team investments and revenue-generation opportunities in commercial and medical affairs.
Mechanism of Action
Interleukin-17A Antagonists
Pharmacologic Class:
Interleukin-17A Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients
Started Oct 2026
186 enrolled
Hidradenitis Suppurativa
A Study to Assess the Safety of Subcutaneous Secukinumab for Treatment in Adult Indian Participants With Axial Spondyloarthritis (axSpA), Ankylosing Spondylitis (AS), and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Started Sep 2026
60 enrolled
Axial SpondyloarthritisAnkylosing SpondylitisNon-Radiographic Axial Spondyloarthritis
A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coronary Plaque Treated With Secukinumab
Started Sep 2026
34 enrolled
Hidradenitis Suppurativa
A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
Started Jul 2026
150 enrolled
Plaque PsoriasisMetabolic Dysfunction-Associated Steatotic Liver Disease
Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
Started Jun 2026
36 enrolled
Hidradenitis Suppurativa (HS)
Worked on COSENTYX at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.